Core Points - MannKind Corporation, in partnership with Alfred E. Mann Charities and The Diabetes Link, launched the Centennial Al Mann Scholarship to honor the legacy of its founder Alfred E. Mann, distributing $100,000 in scholarship funds to support young adults living with diabetes pursuing higher education in life sciences [1][2][8] - The scholarship program aims to empower students aged 18-22 with type 1 or type 2 diabetes, providing up to $10,000 per recipient, distributed in annual installments of $2,500 [3][4] - The initiative reflects Alfred E. Mann's commitment to improving human life through medical advancement and philanthropy, continuing his vision of giving back to the community [2][5] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions, particularly in cardiometabolic and orphan lung diseases [6][7] - The company has a history of developing breakthrough medical devices and treatments, including the inhaled insulin product Afrezza, which was brought to market with a significant investment of nearly $1 billion by Alfred E. Mann [5][6] Partnership and Community Impact - The partnership with The Diabetes Link aims to expand access to higher education for young adults with diabetes, addressing the rising costs of college and easing financial burdens [5][12] - The Diabetes Link is a national nonprofit organization dedicated to empowering young adults living with diabetes through peer support and resources, envisioning a future where they thrive in their personal and professional lives [12]

Core Insights - MannKind Corporation announced that the FDA has accepted the supplemental biologics license application (sBLA) for Afrezza, seeking approval for use in children and adolescents with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026 [1][8] Company Overview - MannKind Corporation is a biopharmaceutical company focused on innovative solutions for chronic diseases, particularly in cardiometabolic and orphan lung diseases, including diabetes [6][7] Product Information - Afrezza is a rapid-acting inhaled human insulin indicated for improving glycemic control in adults with diabetes mellitus, and it has been available for adults since June 2014 [3][4] - If approved for pediatric use, Afrezza would be the first needle-free insulin option for children in over 100 years [8] Clinical Study Details - The sBLA is based on the Phase 3 INHALE-1 study, which involved children and adolescents aged 4-17, comparing Afrezza with multiple daily injections (MDI) [2][8] - The study's six-month topline results were reported in December 2024, and full results will be presented at the International Society for Pediatric and Adolescent Diabetes (ISPAD) in early November [2]

Core Insights - MannKind Corporation will showcase its inhaled insulin product, Afrezza, at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago [1][5] - Dr. Michael J. Haller will present results from the INHALE-1 clinical trial, focusing on inhaled insulin treatment for children and adolescents aged 4-17 [2][3] - MannKind plans to submit a Supplemental Biologics License Application for a pediatric indication for Afrezza in mid-2025, following the release of topline results from the full pediatric data set in Q2 2025 [5] Company Overview - MannKind Corporation specializes in developing and commercializing inhaled therapeutic products and delivery devices for endocrine and orphan lung diseases [6][7] - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [7] Upcoming Events - The ADA's Scientific Sessions will feature a symposium titled "Future Ready," where breakthrough advancements in pediatric Type 1 diabetes care will be discussed [3] - MannKind will host a booth (1617) at the event for scientific exchange and to showcase its products [4]